A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic or unresectable locallyadvanced MTAP-deleted (Homozygous deletion of MTAP) NSCLC

• Participants will have received and progressed or experienced disease recurrence onor after receiving at least 1 prior systemic therapy for locally advanced andunresectable or metastatic disease.

• Either an archival tissue sample or an archival block must be available.

• Life expectancy of greater than 3 months, in the opinion of the investigator.

• Participants who have had brain metastases and have been appropriately treated withradiation therapy or surgery ending at least 14 days before study day 1 areeligible.

• Participants with untreated asymptomatic brain metastases smaller or equal to 2 cmin size (per lesion if more than one) and not requiring corticosteroid treatment areeligible.

Exclusion Criteria:

Disease Related

• Tumors harboring the following mutations amenable to targeted therapies: epidermal growth factor receptor (EGFR), ALK receptor tyrosine kinase (ALK), ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), MET proto-oncogene (MET), B-Raf proto-oncogene (BRAF), RET proto-oncogene (RET), Human epidermal growth factor receptor 2 (HER2/ERBB2), KRAS proto-oncogene G12C (KRAS G12C).

Other Medical Conditions

• Major surgery within 28 days of study day 1.

• Untreated symptomatic central nervous system (CNS) metastatic disease regardless ofsize or asymptomatic brain metastases greater than 2 cm per lesion.